Tocilizumab for severe COVID-19 related illness - A community academic medical center experience.
Kapil S Meleveedu,Kapil S Meleveedu,John Miskovsky,Joseph Meharg,Abd Abdelrahman,Richa Tandon,Ashley E. Moody,Priscilla Dasilva,Priscilla Dasilva,Gabrielle Masse,Jason Laporte,Abdul Saied Calvino,Abdul Saied Calvino,Abdul Saied Calvino,Greg Allen,Rabih El-Bizri,Todd Roberts,Todd Roberts,Vincent Armenio,Vincent Armenio,Steven C. Katz +20 more
- Vol. 2, Iss: 4, pp 100035
TLDR
Outcomes in a series of severely ill patients with COVID-19 CRS following treatment with anti-IL-6/IL- 6-Receptor (anti- IL-6-R) therapy, including tocilizumab or siltuximab are described, and it is believed anti-ISR therapy can be effective in managing early CRS related to CO VID-19 disease.Citations
More filters
Journal ArticleDOI
SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells.
Tapas Patra,Keith Meyer,Lizzie Geerling,T. Scott Isbell,Daniel F. Hoft,James D. Brien,Amelia K. Pinto,Ratna B. Ray,Ranjit Ray +8 more
TL;DR: The results indicated that the presence of SARS-CoV-2 spike protein in epithelial cells promotes IL-6 trans-signaling by activation of the AT1 axis to initiate coordination of a hyper-inflammatory response.
Journal ArticleDOI
Technological exaptation and crisis management: Evidence from COVID-19 outbreaks
TL;DR: In this paper, the authors analyze the patterns of critical innovations to cope with new coronavirus disease (COVID-19) that is generating public health and economic issues worldwide.
Journal ArticleDOI
Beneficial and Harmful Outcomes of Tocilizumab in Severe COVID-19: A Systematic Review and Meta-Analysis
Manuel Rubio-Rivas,Carlos G Forero,José María Mora-Luján,Abelardo Montero,Francesc Formiga,Narcís A. Homs,Joan Albà-Albalate,Laura Sanchez,Jordi Rello,Jordi Rello,Xavier Corbella,Xavier Corbella +11 more
TL;DR: In this paper, the authors aim to update medical evidence from controlled observational studies and randomized clinical trials (RCTs) on the use of TCZ in hospitalized patients with COVID-19.
Journal ArticleDOI
Targeting IL-6 trans-signalling: past, present and future prospects.
TL;DR: The first selective inhibitor of IL-6 trans-signalling, sgp130, has shown therapeutic potential in various preclinical models of disease and olamkicept, a s gp130Fc variant, had promising results in phase II clinical studies for inflammatory bowel disease as discussed by the authors .
Journal ArticleDOI
A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 <i>trans</i> -Signaling and Cellular Infection with SARS-CoV-2
TL;DR: C19s130Fc as mentioned in this paper is a bispecific trans-signaling inhibitor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
Dawei Wang,Bo Hu,Chang Hu,Fangfang Zhu,Xing Liu,Jing Zhang,Binbin Wang,Hui Xiang,Zhenshun Cheng,Yong Xiong,Yan Zhao,Yirong Li,Xinghuan Wang,Zhiyong Peng +13 more
TL;DR: The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described.
Journal ArticleDOI
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta,Daniel F. McAuley,Michael Brown,Emilie Sanchez,Rachel Tattersall,Rachel Tattersall,Jessica J Manson +6 more
TL;DR: Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events.
Journal ArticleDOI
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.
TL;DR: This study conducted a retrospective multicenter study of 68 death cases and 82 discharged cases with laboratory-confirmed infection of SARS-CoV-2 and confirmed that some patients died of fulminant myocarditis, which is characterized by a rapid progress and a severe state of illness.
Journal ArticleDOI
Effective treatment of severe COVID-19 patients with tocilizumab.
Xiaoling Xu,Mingfeng Han,Tiantian Li,Wei Sun,Dongsheng Wang,Binqing Fu,Yonggang Zhou,Xiaohu Zheng,Yun Yang,Xiuyong Li,Xiaohua Zhang,Aijun Pan,Haiming Wei +12 more
TL;DR: Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.
Related Papers (5)
The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome.
Mathieu Blot,Jean-Baptiste Bour,Jean Pierre Quenot,Abderrahmane Bourredjem,Maxime Nguyen,Julien Guy,Serge Monier,Marjolaine Georges,Audrey Large,Auguste Dargent,Alexandre Guilhem,Suzanne Mouries-Martin,Jeremy Barben,Belaid Bouhemad,Pierre-Emmanuel Charles,P. Chavanet,Christine Binquet,Christine Binquet,Lionel Piroth +18 more